GB2573406B - Tumor infiltrating lymphocytes and methods of therapy - Google Patents

Tumor infiltrating lymphocytes and methods of therapy Download PDF

Info

Publication number
GB2573406B
GB2573406B GB1906855.0A GB201906855A GB2573406B GB 2573406 B GB2573406 B GB 2573406B GB 201906855 A GB201906855 A GB 201906855A GB 2573406 B GB2573406 B GB 2573406B
Authority
GB
United Kingdom
Prior art keywords
therapy
methods
tumor infiltrating
infiltrating lymphocytes
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1906855.0A
Other languages
English (en)
Other versions
GB2573406A (en
GB201906855D0 (en
Inventor
Moriarity Branden
Webber Beau
Choudhry Modassir
A Rosenberg Steven
C Palmer Douglas
P Restifo Nicholas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota Twin Cities
Intima Bioscience Inc
University of Minnesota System
US Department of Health and Human Services
Original Assignee
University of Minnesota Twin Cities
Intima Bioscience Inc
University of Minnesota System
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota Twin Cities, Intima Bioscience Inc, University of Minnesota System, US Department of Health and Human Services filed Critical University of Minnesota Twin Cities
Priority to GB2113770.8A priority Critical patent/GB2604416B/en
Publication of GB201906855D0 publication Critical patent/GB201906855D0/en
Publication of GB2573406A publication Critical patent/GB2573406A/en
Application granted granted Critical
Publication of GB2573406B publication Critical patent/GB2573406B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/52—Intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
GB1906855.0A 2016-10-18 2017-10-18 Tumor infiltrating lymphocytes and methods of therapy Active GB2573406B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB2113770.8A GB2604416B (en) 2016-10-18 2017-10-18 Tumor infiltating lymphocytes and methods of therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662409651P 2016-10-18 2016-10-18
US201762452244P 2017-01-30 2017-01-30
PCT/US2017/057228 WO2018075664A1 (en) 2016-10-18 2017-10-18 Tumor infiltrating lymphocytes and methods of therapy

Publications (3)

Publication Number Publication Date
GB201906855D0 GB201906855D0 (en) 2019-06-26
GB2573406A GB2573406A (en) 2019-11-06
GB2573406B true GB2573406B (en) 2021-11-10

Family

ID=62019385

Family Applications (4)

Application Number Title Priority Date Filing Date
GB1906855.0A Active GB2573406B (en) 2016-10-18 2017-10-18 Tumor infiltrating lymphocytes and methods of therapy
GB2205417.5A Active GB2605883B (en) 2016-10-18 2017-10-18 Tumor infiltrating lymphocytes and methods of therapy
GB2113770.8A Active GB2604416B (en) 2016-10-18 2017-10-18 Tumor infiltating lymphocytes and methods of therapy
GB2209032.8A Active GB2605540B (en) 2016-10-18 2017-10-18 Tumor infiltrating lymphocytes and methods of therapy

Family Applications After (3)

Application Number Title Priority Date Filing Date
GB2205417.5A Active GB2605883B (en) 2016-10-18 2017-10-18 Tumor infiltrating lymphocytes and methods of therapy
GB2113770.8A Active GB2604416B (en) 2016-10-18 2017-10-18 Tumor infiltating lymphocytes and methods of therapy
GB2209032.8A Active GB2605540B (en) 2016-10-18 2017-10-18 Tumor infiltrating lymphocytes and methods of therapy

Country Status (8)

Country Link
US (5) US10912797B2 (enExample)
EP (2) EP3529359B1 (enExample)
JP (3) JP7181862B2 (enExample)
CN (1) CN110520530A (enExample)
AU (2) AU2017346885B2 (enExample)
CA (1) CA3041068A1 (enExample)
GB (4) GB2573406B (enExample)
WO (1) WO2018075664A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201601660YA (en) 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
EP3299030B1 (en) 2011-07-11 2022-06-08 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
GB2557123B (en) 2015-07-31 2021-11-03 Univ Minnesota Modified cells and methods of therapy
GB2573406B (en) * 2016-10-18 2021-11-10 Univ Minnesota Tumor infiltrating lymphocytes and methods of therapy
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
BR112020008568A2 (pt) * 2017-11-09 2020-10-06 Sangamo Therapeutics, Inc. modificação genética de gene de proteína contendo sh2 indutível por citoquina (cish)
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
EP3784254A1 (en) * 2018-04-27 2021-03-03 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20210254068A1 (en) * 2018-06-19 2021-08-19 Regents Of The University Of Minnesota Genome engineering primary monocytes
CN116144706A (zh) 2018-08-13 2023-05-23 根路径基因组学公司 成对的二分免疫受体多核苷酸的高通量克隆及其应用
EP3852524B1 (en) * 2018-09-20 2023-06-28 Iovance Biotherapeutics, Inc. Expansion of tils from cryopreserved tumor samples
EP3887395A4 (en) * 2018-11-30 2022-07-27 Intima Bioscience, Inc. METHODS FOR IDENTIFICATION OF IMMUNOMODULATORY GENES
EP3947436A4 (en) 2019-04-05 2022-12-28 Rootpath Genomics, Inc. COMPOSITIONS AND METHODS FOR ASSEMBLING T LYMPHOCYTE RECEPTOR GENE
US12188045B2 (en) 2019-06-07 2025-01-07 KSQ Therapeutics, Inc. Guide RNA combinations and methods of use
AU2020304022A1 (en) * 2019-06-24 2022-02-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. A peptide-based screening method to identify neoantigens for use with tumor infiltrating lymphocytes
KR102902719B1 (ko) 2019-10-18 2025-12-24 포티 세븐, 엘엘씨 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
WO2021081378A1 (en) * 2019-10-25 2021-04-29 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
CN110628717B (zh) * 2019-10-28 2020-10-30 上海科医联创生物科技有限公司 一种浸润性t细胞的培养方法
CA3153636A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
CA3162896A1 (en) * 2019-11-27 2021-06-03 Board Of Regents, The University Of Texas System Engineered t cells and tumor-infiltrating lymphocytes to overcome immunosuppression in the tumor microenvironment
BR112022011702A2 (pt) * 2019-12-18 2022-09-06 Cbio As Processo melhorado para cultura de linfócitos infiltrantes tumorais para uso terapêutico
KR20220119439A (ko) 2019-12-20 2022-08-29 인스틸 바이오 유케이 리미티드 종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도
EP4445902A3 (en) 2019-12-24 2024-12-18 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
CN116018158A (zh) * 2020-04-30 2023-04-25 转化基因组学研究所 新抗原知情的肿瘤浸润性淋巴细胞癌免疫疗法
KR20230040348A (ko) * 2020-07-15 2023-03-22 더 잭슨 래보라토리 Sars-cov-2 감염에 대한 인간화 마우스 모델
WO2022082216A1 (en) * 2020-10-14 2022-04-21 Loma Linda Faculty Medical Group Combination of adoptive cell therapy and chemotherapy for acute myeloid leukemia
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
WO2022125633A1 (en) * 2020-12-08 2022-06-16 The Regents Of The University Of California Crispr ribonucleoprotein complex genome editing of human innate immune cells
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2022192536A1 (en) * 2021-03-11 2022-09-15 The Methodist Hospital Methods and compositions for treatment of disease
JP2024511414A (ja) * 2021-03-23 2024-03-13 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球のｃｉｓｈ遺伝子編集及び免疫療法におけるその使用
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240052771A (ko) * 2021-09-08 2024-04-23 케이에스큐 세러퓨틱스 인코포레이티드 림프구 효력 검정
CN113952475B (zh) * 2021-09-27 2025-03-11 中国人民解放军陆军军医大学 淋巴细胞和介导crispr系统的纳米复合物联合在制备治疗宫颈癌药物中的应用
CN118525084A (zh) * 2022-01-19 2024-08-20 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞在疾病治疗中的用途
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2025096638A2 (en) * 2023-10-30 2025-05-08 Turnstone Biologics Corp. Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025250550A1 (en) * 2024-05-28 2025-12-04 Ctrl Therapeutics Usa, Inc. Enhanced expansion of tumor-reactive lymphocytes for cancer treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220488A1 (en) * 2005-08-31 2009-09-03 Humphrey Gardner Evaluating and treating scleroderma
US20150259684A1 (en) * 2013-07-10 2015-09-17 President And Fellows Of Harvard College Orthogonal Cas9 Proteins for RNA-Guided Gene Regulation and Editing
WO2015143328A1 (en) * 2014-03-20 2015-09-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tumor-infiltrating lymphocytes for adoptive cell therapy
US20170065636A1 (en) * 2015-07-31 2017-03-09 Regents Of The University Of Minnesota Modified cells and methods of therapy

Family Cites Families (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
US5830755A (en) 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO1998006746A2 (en) 1996-08-16 1998-02-19 The Johns Hopkins University School Of Medicine Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same
DE69718029T2 (de) 1996-10-11 2003-10-16 The Regents Of The University Of California, Oakland Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
US6323317B1 (en) * 1996-11-01 2001-11-27 The Walter And Eliza Hall Institute Of Medical Research Therapeutic and diagnostics proteins comprising a SOCS box
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2002535995A (ja) 1999-02-03 2002-10-29 ザ チルドレンズ メディカル センター コーポレイション 染色体標的部位での二本鎖ｄｎａ切断の誘導を含む遺伝子修復
JP2000256212A (ja) * 1999-03-05 2000-09-19 Tadayasu Takada 良性間葉系腫瘍の治療剤
EP2311951A1 (en) 2000-01-28 2011-04-20 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
EP1330156A4 (en) 2000-10-09 2006-09-13 Amrad Operations Pty Ltd MODULATION OF CYTOKINE OR HORMONE SIGNALING IN AN ANIMAL, INTEGRATING PROGRESSIVE REGULATION OF SOCS SEQUENCE EXPRESSION IN ANIMALS
US8716022B2 (en) 2000-11-17 2014-05-06 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Modulation of meiotic recombination
US7723111B2 (en) 2001-03-09 2010-05-25 The United States Of America As Represented By The Department Of Health And Human Services Activated dual specificity lymphocytes and their methods of use
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
MXPA04001974A (es) 2001-08-31 2004-07-16 Avidex Ltd Receptor de celula t soluble.
EP2034009B1 (en) 2002-02-08 2014-01-15 Life Technologies Corporation Compositions and methods for restoring immune responsiveness in patients with immunological defects basing on cd3/cd28 costimulation
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP1517992B1 (en) 2002-06-05 2013-08-21 Her Majesty the Queen in Right of Canada, as represented by the Minister of Agriculture and Agri-Food Retrons for gene targeting
US8034334B2 (en) * 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
HUE054805T2 (hu) 2003-09-30 2021-09-28 Univ Pennsylvania Adeno-asszociált vírus (AAV) kládok, szekvenciák, az azokat tartalmazó vektorok és alkalmazásaik
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
EP1756278B1 (en) 2004-05-19 2008-09-17 MediGene Ltd. Method of improving t cell receptors
JP4773434B2 (ja) 2004-05-19 2011-09-14 イムノコア リミテッド 高親和性ｎｙ−ｅｓｏｔ細胞受容体
WO2006112869A2 (en) 2004-07-19 2006-10-26 Baylor College Of Medicine Modulation of cytokine signaling regulators and applications for immunotherapy
US8889365B2 (en) 2005-03-16 2014-11-18 Rutgers, The State University Of New Jersey Methods and kit for detecting breast cancer
EP3085389A1 (en) 2005-04-07 2016-10-26 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
US8389708B2 (en) 2005-06-15 2013-03-05 Weiping Min Method of cancer treatment using siRNA silencing
DK1910521T3 (da) 2005-08-05 2011-02-07 Helmholtz Zentrum Muenchen Generering af allo-begrænsede, antigenspecifikke T-celler
NZ597299A (en) 2005-08-26 2013-03-28 Dupont Nutrition Biosci Aps Use of a cas gene in combination with CRISPR repeats for modulating resistance in a cell
ES2543629T3 (es) 2006-05-17 2015-08-20 Hoffmann-La Roche Ag Células productoras de polipéptidos
US9399801B2 (en) 2006-05-19 2016-07-26 Dupont Nutrition Biosciences Aps Tagged microorganisms and methods of tagging
EP1878744A1 (en) 2006-07-13 2008-01-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them
US7750449B2 (en) 2007-03-13 2010-07-06 Micron Technology, Inc. Packaged semiconductor components having substantially rigid support members and methods of packaging semiconductor components
PL2856876T3 (pl) 2007-03-30 2018-06-29 Memorial Sloan-Kettering Cancer Center Konstytutywna ekspresja ligandów kostymulujących na limfocytach T poddanych transferowi adoptywnemu
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
US8822647B2 (en) 2008-08-26 2014-09-02 City Of Hope Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
US9404098B2 (en) 2008-11-06 2016-08-02 University Of Georgia Research Foundation, Inc. Method for cleaving a target RNA using a Cas6 polypeptide
US8889641B2 (en) 2009-02-11 2014-11-18 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
US20120192298A1 (en) 2009-07-24 2012-07-26 Sigma Aldrich Co. Llc Method for genome editing
US8383099B2 (en) * 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
WO2011117258A2 (en) 2010-03-22 2011-09-29 Association Institut De Myologie Methods of increasing efficiency of vector penetration of target tissue
KR102095670B1 (ko) * 2010-05-14 2020-03-31 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
JP5261448B2 (ja) * 2010-08-09 2013-08-14 古河電気工業株式会社 空孔アシスト光ファイバ
WO2012033885A1 (en) 2010-09-08 2012-03-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered gd2-specific t cells
WO2012078540A1 (en) 2010-12-08 2012-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulating immune cell activity using cytokine-induced src homology 2 and/or high temperature requirement a-1
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012112079A1 (en) 2011-02-14 2012-08-23 Vitaspero, Inc. IMPROVING CELLULAR IMMUNOTHERAPEUTIC VACCINES EFFICACY WITH GENE SUPPRESSION IN DENDRITIC CELLS AND T-LYMPHOCYTES USING SiRNA
US9528124B2 (en) 2013-08-27 2016-12-27 Recombinetics, Inc. Efficient non-meiotic allele introgression
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
EP3219313B1 (en) 2011-04-18 2020-10-28 National Center of Neurology and Psychiatry Drug delivery particle and method for producing the same
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
US9096642B2 (en) 2011-06-08 2015-08-04 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
KR101307196B1 (ko) 2011-07-15 2013-09-12 국립대학법인 울산과학기술대학교 산학협력단 미세 세포 배양 장치
US10421960B2 (en) 2011-09-16 2019-09-24 The Trustees Of The University Of Pennsylvania RNA engineered T cells for the treatment of cancer
WO2013049330A1 (en) 2011-09-28 2013-04-04 The Regents Of The University Of California Synthetic transcriptional control elements and methods of generating and using such elements
US9279159B2 (en) 2011-10-21 2016-03-08 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
US9688740B2 (en) 2011-10-26 2017-06-27 National Cancer Center Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
EP2790708B1 (en) 2011-12-16 2024-10-23 Targetgene Biotechnologies Ltd. Compositions and methods for modifying a predetermined target nucleic acid sequence
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
CN104507963B (zh) 2012-05-22 2017-12-15 美国卫生和人力服务部 鼠抗‑ny‑eso‑1 t细胞受体
EP4541818A3 (en) 2012-05-25 2025-07-23 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
LT3401400T (lt) 2012-05-25 2019-06-10 The Regents Of The University Of California Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
US9969696B2 (en) 2012-07-04 2018-05-15 Indian Institute Of Science Compounds as inhibitor of DNA double-strand break repair, methods and applications thereof
JP2015527889A (ja) 2012-07-25 2015-09-24 ザ ブロード インスティテュート， インコーポレイテッド 誘導可能なｄｎａ結合タンパク質およびゲノム撹乱ツール、ならびにそれらの適用
WO2014022702A2 (en) 2012-08-03 2014-02-06 The Regents Of The University Of California Methods and compositions for controlling gene expression by rna processing
PL3824905T3 (pl) 2012-08-20 2025-05-05 Fred Hutchinson Cancer Center Sposób i kompozycje do immunoterapii komórkowej
EP3763810A3 (en) * 2012-10-10 2021-07-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
US20140113375A1 (en) 2012-10-21 2014-04-24 Lixin Liu Transient Expression And Reverse Transcription Aided Genome Alteration System
PL4397760T3 (pl) 2012-10-23 2026-03-30 Toolgen Incorporated Kompozycja do rozszczepiania docelowego dna zawierająca prowadzące rna specyficzne dla docelowego dna i kwas nukleinowy kodujący białko cas lub białko cas oraz jej zastosowanie
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
EP3135765A1 (en) 2012-12-06 2017-03-01 Sigma-Aldrich Co. LLC Crispr-based genome modification and regulation
EP2896697B1 (en) 2012-12-12 2015-09-02 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
JP2016504026A (ja) 2012-12-12 2016-02-12 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のための系、方法および最適化ガイド組成物のエンジニアリング
ES2576126T3 (es) 2012-12-12 2016-07-05 The Broad Institute, Inc. Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN114634950A (zh) 2012-12-12 2022-06-17 布罗德研究所有限公司 用于序列操纵的crispr-cas组分系统、方法以及组合物
EP2931898B1 (en) 2012-12-12 2016-03-09 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
IL239317B (en) 2012-12-12 2022-07-01 Broad Inst Inc Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications
EP3434776A1 (en) 2012-12-12 2019-01-30 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
SG10201912991WA (en) 2012-12-17 2020-03-30 Harvard College Rna-guided human genome engineering
WO2014127287A1 (en) 2013-02-14 2014-08-21 Massachusetts Institute Of Technology Method for in vivo tergated mutagenesis
EP2958996B1 (en) 2013-02-25 2019-10-16 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
BR112015020516A2 (pt) 2013-02-26 2017-10-10 Memorial Sloan Kettering Cancer Center composições e métodos para imunoterapia
US9393257B2 (en) 2013-03-01 2016-07-19 Regents Of The University Of Minnesota TALEN-based gene correction
WO2014153118A1 (en) 2013-03-14 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
SG11201507378UA (en) 2013-03-14 2015-10-29 Caribou Biosciences Inc Compositions and methods of nucleic acid-targeting nucleic acids
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US10378027B2 (en) 2013-03-15 2019-08-13 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
JP2016522679A (ja) 2013-04-04 2016-08-04 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
US11311575B2 (en) 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
RU2725542C2 (ru) 2013-05-13 2020-07-02 Селлектис Способы конструирования высокоактивных т-клеток для иммунотерапии
EP3730615A3 (en) 2013-05-15 2020-12-09 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
ES2670531T3 (es) 2013-05-29 2018-05-30 Cellectis S.A. Un método para producir una escisión de ADN precisa utilizando la actividad nickasa de Cas9
DK3309248T3 (da) 2013-05-29 2021-08-02 Cellectis Fremgangsmåde til manipulering af T-celler til immunterapi under anvendelse af et RNA-guidet CAS-nuklease-system
ES2883131T3 (es) 2013-05-29 2021-12-07 Cellectis Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
JP6195474B2 (ja) 2013-05-31 2017-09-13 ギガフォトン株式会社 極端紫外光生成装置及び極端紫外光生成システムにおけるレーザシステムの制御方法
JP6665088B2 (ja) 2013-06-17 2020-03-13 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のための最適化されたＣＲＩＳＰＲ−Ｃａｓ二重ニッカーゼ系、方法および組成物
MX2015017312A (es) 2013-06-17 2017-04-10 Broad Inst Inc Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas.
WO2014204724A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
WO2014204723A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions
CN105793425B (zh) 2013-06-17 2021-10-26 布罗德研究所有限公司 使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用
EP3725885A1 (en) 2013-06-17 2020-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
JP6738729B2 (ja) 2013-06-17 2020-08-12 ザ・ブロード・インスティテュート・インコーポレイテッド 分裂終了細胞の疾患および障害をターゲティングおよびモデリングするための系、方法および組成物の送達、エンジニアリングおよび最適化
WO2015002293A1 (ja) * 2013-07-05 2015-01-08 学校法人岩手医科大学 Ｗｎｔシグナル阻害剤
JP2016528890A (ja) 2013-07-09 2016-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いるゲノム編集の治療用の使用
US20150020233A1 (en) 2013-07-12 2015-01-15 Oms Investments, Inc. Plants comprising events pp009-401, pp009-415, and pp009-469, compositions, sequences, and methods for detection thereof
US10563225B2 (en) 2013-07-26 2020-02-18 President And Fellows Of Harvard College Genome engineering
US20150044772A1 (en) 2013-08-09 2015-02-12 Sage Labs, Inc. Crispr/cas system-based novel fusion protein and its applications in genome editing
CA3221516A1 (en) 2013-08-22 2015-02-26 E. I. Du Pont De Nemours And Company Plant genome modification using guide rna/cas endonuclease systems and methods of use
CN104427476B (zh) 2013-09-10 2019-05-07 中兴通讯股份有限公司 位置信息上报方法、集群服务处理方法及系统
WO2015048577A2 (en) 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
WO2015048690A1 (en) 2013-09-27 2015-04-02 The Regents Of The University Of California Optimized small guide rnas and methods of use
US20150098954A1 (en) 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
DE102013111099B4 (de) 2013-10-08 2023-11-30 Eberhard Karls Universität Tübingen Medizinische Fakultät Permanente Genkorrektur mittels nukleotidmodifizierter messenger RNA
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
CA2930877A1 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
US10787684B2 (en) 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
JP2016538001A (ja) 2013-11-28 2016-12-08 ホライズン・ジェノミクス・ゲーエムベーハー 体細胞半数体ヒト細胞株
CN106061488B (zh) 2013-12-02 2021-04-09 菲奥医药公司 癌症的免疫治疗
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
BR112016013213A2 (pt) 2013-12-12 2017-12-05 Massachusetts Inst Technology administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para visar distúrbios e doenças usando componentes de administração de partículas
CN103820454B (zh) 2014-03-04 2016-03-30 上海金卫生物技术有限公司 CRISPR-Cas9特异性敲除人PD1基因的方法以及用于特异性靶向PD1基因的sgRNA
MX373460B (es) 2014-03-11 2020-04-07 Cellectis Metodo para generar celulas t compatibles para el trasplante alogenico.
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
EP3129490A4 (en) 2014-04-08 2017-10-04 North Carolina State University Methods and compositions for rna-directed repression of transcription using crispr-associated genes
WO2015157534A1 (en) 2014-04-10 2015-10-15 The Regents Of The University Of California Methods and compositions for using argonaute to modify a single stranded target nucleic acid
KR102595473B1 (ko) 2014-04-18 2023-10-30 에디타스 메디신, 인코포레이티드 암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분
IL313845A (en) 2014-04-23 2024-08-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
EP3151846A4 (en) 2014-06-05 2017-12-27 Sangamo BioSciences, Inc. Methods and compositions for nuclease design
US20170224731A1 (en) 2014-06-10 2017-08-10 Monash University Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
WO2015191693A2 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
TWI530276B (zh) 2014-07-08 2016-04-21 原相科技股份有限公司 具去噪功能之生理偵測模組及其生理偵測方法
AU2015289644A1 (en) 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
JP2017522884A (ja) * 2014-07-29 2017-08-17 ファイザー・インク がん免疫療法のためのＥＧＦＲｖＩＩＩ特異的キメラ抗原受容体
IL287561B2 (en) 2014-10-01 2024-03-01 Massachusetts Gen Hospital Methods for increasing efficiency of nuclease-induced homology-directed repair
CN107074932A (zh) 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
KR20170075013A (ko) 2014-10-31 2017-06-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Cart 세포에서 유전자 발현의 변경 및 그의 용도
WO2016089433A1 (en) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
CA2972454C (en) 2014-12-31 2024-09-10 Phykion Inc. Compositions and methods for high efficiency in in vivo genome editing
US10280451B2 (en) 2015-01-09 2019-05-07 Bio-Rad Laboratories, Inc. Detection of genome editing
CN107429263A (zh) 2015-01-15 2017-12-01 斯坦福大学托管董事会 调控基因组编辑的方法
KR102422108B1 (ko) 2015-01-20 2022-07-19 삼성디스플레이 주식회사 유기 발광 표시 장치
AU2016243583B2 (en) * 2015-03-27 2022-03-10 President And Fellows Of Harvard College Modified T cells and methods of making and using the same
EP3294343A4 (en) 2015-05-13 2018-09-26 Seattle Children's Hospital, dba Seattle Children's Research Institute Enhancing endonuclease based gene editing in primary cells
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CN108024544B (zh) 2015-07-13 2022-04-29 桑格摩生物治疗股份有限公司 用于核酸酶介导的基因组工程化的递送方法及组合物
JP2019505498A (ja) 2015-12-16 2019-02-28 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害
US9570114B1 (en) 2016-01-15 2017-02-14 HGST Netherlands B.V. Laminated film-packed hard disk drive for hermetic sealing
US11746349B2 (en) 2016-02-09 2023-09-05 President And Fellows Of Harvard College DNA-guided gene editing and regulation
MX2019000149A (es) * 2016-07-07 2019-09-23 Iovance Biotherapeutics Inc Proteinas de union a ligando 1 de muerte programada 1 (pd-l1) y metodos de uso de las mismas.
GB2573406B (en) * 2016-10-18 2021-11-10 Univ Minnesota Tumor infiltrating lymphocytes and methods of therapy
CN111344396A (zh) 2016-10-27 2020-06-26 因提玛生物科学公司 制备遗传修饰细胞的病毒方法
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
CN111836891A (zh) 2017-09-07 2020-10-27 莱兰斯坦福初级大学评议会 用于基因工程的核酸酶系统

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220488A1 (en) * 2005-08-31 2009-09-03 Humphrey Gardner Evaluating and treating scleroderma
US20150259684A1 (en) * 2013-07-10 2015-09-17 President And Fellows Of Harvard College Orthogonal Cas9 Proteins for RNA-Guided Gene Regulation and Editing
WO2015143328A1 (en) * 2014-03-20 2015-09-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tumor-infiltrating lymphocytes for adoptive cell therapy
US20170065636A1 (en) * 2015-07-31 2017-03-09 Regents Of The University Of Minnesota Modified cells and methods of therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"CLINICALTRIALS.GOV: ARCHIVE: NCI 00501995 on 201G_10_09", U.S. National Institute of Health., 09 October 2016, URL: https://clinicaltrials.gov/archive/NCT00501995/2016_1 0 09, Retrieved 10.1.2018 *
HU , G et al., "MicroRNA-98 and let-7 Confer Cholangiocyte Expression of Cytokine-Inducible Src Homology 2-Containing Protein in Response to Microbial Challenge", Journal of Immunology, 10 July 2009, vol. 183, no. 3, pages 1 - 7, page 6, paragraph 3; DOI:10.4049/jimmunol.0804362 *
PALMER, DC et al., "Cish Actively Silences TCR Signaling in CD 8+ T Cells to Maintain Tumor Tolerance", The Journal of Experimental Medicine, 02 November 2015, vol. 212, no. 12, pages 2095 - 2113, : page 2098, column 1, paragraph 2; DOI: 10.1084/jem.20150304 * *
SHI, D et al., "Silenced Suppressor of Cytokine Signaling 1 (SOCS1) Enhances the Maturation and Antifungal Immunity of Dendritic Cells in Response to Candida Albicans In Vitro",Immunological Research, 09 Nov 2014; vol.61,no.3, pp.206 - 218, p.208, col 1, par 2; p.209, col 1 par 3; p.209 col 2, par 4 *

Also Published As

Publication number Publication date
GB2604416A (en) 2022-09-07
JP2019532080A (ja) 2019-11-07
GB2605540A (en) 2022-10-05
EP3529359B1 (en) 2023-12-13
GB202209032D0 (en) 2022-08-10
US20190008899A1 (en) 2019-01-10
GB2604416B (en) 2023-03-15
WO2018075664A1 (en) 2018-04-26
US11154574B2 (en) 2021-10-26
JP2022162155A (ja) 2022-10-21
AU2022200267A1 (en) 2022-02-10
US10912797B2 (en) 2021-02-09
JP7181862B2 (ja) 2022-12-01
GB2605540B (en) 2022-12-21
GB2573406A (en) 2019-11-06
AU2017346885A1 (en) 2019-05-16
JP2022059055A (ja) 2022-04-12
US20220105133A1 (en) 2022-04-07
US20200289571A1 (en) 2020-09-17
GB2605883B (en) 2023-03-15
EP3529359A1 (en) 2019-08-28
GB202113770D0 (en) 2021-11-10
GB202205417D0 (en) 2022-05-25
GB201906855D0 (en) 2019-06-26
AU2017346885B2 (en) 2021-10-21
CN110520530A (zh) 2019-11-29
CA3041068A1 (en) 2018-04-26
GB2605883A (en) 2022-10-19
US20200330517A1 (en) 2020-10-22
EP3529359A4 (en) 2020-06-03
EP4338799A2 (en) 2024-03-20
EP4338799A3 (en) 2024-06-05
US20200289570A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
GB2605540B (en) Tumor infiltrating lymphocytes and methods of therapy
IL266655A (en) Lymphocytes infiltrating residual tumor and methods for their preparation and use
IL265759A (en) Therapeutic and diagnostic methods for cancer
GB2557123B (en) Modified cells and methods of therapy
IL258955A (en) Compositions and methods for treatment of cancer
IL255372A0 (en) Therapeutic and diagnostic methods for cancer
PL3294770T5 (pl) Sposoby terapeutyczne i diagnostyczne stosowane w przypadku nowotworu
SG10201912792YA (en) Therapeutic compounds and methods
IL265881A (en) Inhaler and methods of use thereof
PL3242947T3 (pl) Terapia genowa i elektroporacja do leczenia zmian złośliwych
IL253160A0 (en) Cancer markers and methods of using them
IL256515A (en) Therapeutic peptides and methods of use thereof
SG11201701035SA (en) Cancer diagnosis and therapy
SG11201708624YA (en) Therapeutic antibodies and uses thereof
IL265955A (en) Therapeutic compounds and methods of using them
SG10202010420TA (en) Patient interface and aspects thereof
IL270011B (en) Medicinal compounds and methods
SG11201707949XA (en) Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy
ZA201802134B (en) Therapeutic compounds and methods of use thereof
GB201411172D0 (en) Respiratory therapy appartus and methods
IL265971B (en) Therapeutic materials and methods for their production
GB201514015D0 (en) Novel pyridazinones and their use in the treatment of cancer
EP3157524A4 (en) Methods of treating cancer and preventing cancer drug resistance
IL256763A (en) Compositions and methods for treating cancer
GB201717004D0 (en) Methods of cancer therapy